{
    "eid": "2-s2.0-85011066657",
    "title": "Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients",
    "cover-date": "2017-03-01",
    "subject-areas": [
        {
            "$": "Pharmacology (medical)",
            "@code": "2736"
        },
        {
            "$": "Microbiology (medical)",
            "@code": "2726"
        },
        {
            "$": "Infectious Diseases",
            "@code": "2725"
        }
    ],
    "keywords": [
        "Atazanavir",
        "Dose optimisation",
        "HIV-infected patients",
        "NONMEM",
        "Population pharmacokinetics",
        "Thai patients"
    ],
    "authors": [
        "Baralee Punyawudho"
    ],
    "citedby-count": 7,
    "ref-count": 42,
    "ref-list": [
        "Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand",
        "Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir",
        "Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: A cross-sectional study",
        "Intrapatient Variability of Efavirenz Concentrations as a Predictor of Virologic Response to Antiretroviral Therapy",
        "Rev Antiviral Ther",
        "Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection",
        "Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy",
        "J AIDS Clin Res",
        "A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults",
        "Low-dose, once-daily atazanavir/ritonavir (200/100): An effective treatment for HIV-infected patients in Thailand",
        "Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy",
        "Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography",
        "The international interlaboratory quality control program for measurement of antiretroviral drugs in plasma: A global proficiency testing program",
        "Effect of Adherence as Measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients",
        "Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies",
        "Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers",
        "Xpose - An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM",
        "Stability and performance of a population pharmacokinetic model",
        "Model appropriateness and population pharmacokinetic modeling",
        "A new equivalence based metric for predictive check to qualify mixed-effects models",
        "Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check",
        "Evaluation of boosted and unboosted atazanavir plasma concentration in HIV infected patients",
        "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202",
        "Sex Differences in Pharmacokinetics and Pharmacodynamics",
        "Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment",
        "Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men",
        "Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice",
        "Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients",
        "Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms",
        "A population pharmacokinetic-pharmacogenetic analysis of atazanavir",
        "Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia",
        "Population pharmacokinetic modeling of the association between 63396C\u2192T pregnane X receptor polymorphism and unboosted atazanavir clearance",
        "Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C\u2192T) with reduced concentrations of unboosted atazanavir",
        "Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia",
        "Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients",
        "Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients",
        "Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients",
        "Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir",
        "Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring",
        "Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients",
        "Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chiang Mai",
            "affilname": "Chiang Mai University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Royal Australasian College of Physicians",
        "Thailand Research Fund",
        "Thailand Research Fund",
        "National Research Council of Thailand",
        "National Research Council of Thailand"
    ]
}